Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
23 sept. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results...
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
14 août 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) announces today that it will present at ESC Congress 2019, held this year in Paris,...
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
15 juil. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, July 15, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone (RVX-208)...
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
08 juil. 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s...
Resverlogix Announces Participation at Leading, International Scientific Conferences
10 juin 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences...
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
06 mai 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, May 06, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: “Multicenter Preclinical...
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
18 avr. 2019 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, April 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration...
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
01 avr. 2019 11h00 HE
|
Resverlogix Corp
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic...
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
18 mars 2019 12h00 HE
|
Resverlogix Corp
CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement of a $2.9 million project led by academic...
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
19 déc. 2018 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed...